In diabetic nephropathy, it significantly reduces NF-κB and TGF-β levels [72], while in left ventricular hypertrophy, benazepril reduces TGF-β, VCAM-1, and NF-κB expression, and ROI’s production. Here, NFKB1 is linked to diabetic kidney disease.